In recent months, Peregrine has implemented a number of initiatives to accelerate its three lead clinical programs.
Bavituximab Solid Tumor Clinical Program
In support of the Phase II bavituximab cancer program, Peregrine filed protocols for two breast cancer combination therapy trials and has already received regulatory approval to proceed with one of those protocols, which is assessing bavituximab in combination with docetaxel in patients with breast cancer. Patient enrollment in this trial is expected to begin in early 2008. Regulatory approval for the second breast cancer trial and for a previously filed combination therapy trial in patients with non-small cell lung cancer is expected early in 2008. The company also is taking action to accelerate its Phase I bavituximab cancer trial in the U.S., with the goal of laying the foundation for U.S. Phase II studies. Peregrine recently added a new study site in Charlotte, North Carolina, and a total of five clinical sites are now screening and recruiting patients for this study. Peregrine expects to complete the Phase I trial during 2008. The bavituximab cancer clinical program will be discussed at an important scientific forum when interim clinical data is presented in February 2008 at the 10th Annual International Symposium on Anti-Angiogenic Agents (Angio 2008).
Bavituximab Hepatitis C Virus (HCV) Clinical Program
The company's trial of bavituximab in HCV patients co-infected with HIV
began enrolling and dosing patients, and with the addition of new clinical
sites at The Johns Hopkins Hospital and a private clinic in Orange County,
California, a total of three clinical sites are now screening and
recruiting patients in this innovative study. The bavituximab HCV clinical
program was awarded an oral presentation slot for the second year in a row
at the prestigious Annual Meeting of the American Association for the Study
of Liver Disease held last November. Final results from the Phase
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved